MGWM
PCVX icon

Marks Group Wealth Management’s Vaxcyte PCVX Stock Holding History

Marks Group Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Buy
7,224
+666
+10% +$36.2K 0.04% 288
2026
Q1 		$381K Buy
+6,558
New +$356K 0.04% 272

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Marks Group Wealth Management's PCVX Position: Q2 2026 in Review

Marks Group Wealth Management increased its Vaxcyte (PCVX) stake by 10% in Q2 2026, buying an estimated $36.2K and bringing the position to 7,224 shares worth $420K. The position accounts for 0.04% of the portfolio, ranked #288.

Marks Group Wealth Management first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Marks Group Wealth Management held 7,224 shares of Vaxcyte worth $420K as of Q2 2026.
  • Marks Group Wealth Management bought 666 Vaxcyte shares in Q2 2026, an estimated $36.2K.
  • Vaxcyte made up 0.04% of Marks Group Wealth Management's portfolio in Q2 2026, its #288 holding.
  • Marks Group Wealth Management first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Marks Group Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.